BRAF and colorectal carcinoma: Gene-expression profiling studies have established that BRAFV600E-mutant BRAF-mt CRC is enriched in a molecularly and clinically distinct disease subtype, which is frequently associated with hypermethylation, MSI, limited chromosomal instability, consensus molecular subtype 1, a higher rate of recurrence in an adjuvant setting and poor survival outcomes in the metastatic setting.14,15